Treatment outcomes among high‐risk neuroblastoma patients receiving non‐immunotherapy regimen: Multicenter study on behalf of the Thai Pediatric Oncology Group

Background Neuroblastoma is the most common extracranial malignant solid tumor during childhood. Despite intensified treatment, patients with high‐risk neuroblastoma (HR‐NBL) still carry a dismal prognosis. The Thai Pediatric Oncology Group (ThaiPOG) proposed the use of a multimodality treatment to...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Pediatric blood & cancer 2022-09, Vol.69 (9), p.e29757-n/a
Hauptverfasser:	Suwannaying, Kunanya, Monsereenusorn, Chalinee, Rujkijyanont, Piya, Techavichit, Piti, Phuakpet, Kamon, Pongphitcha, Pongpak, Chainansamit, Su‐on, Chotsampancharoen, Thirachit, Winaichatsak, Angkana, Traivaree, Chanchai, Sathitsamitphong, Lalita, Kanjanapongkul, Somjai, Komvilaisak, Patcharee, Sanpakit, Kleebsabai, Photia, Apichat, Seksarn, Panya, Wiangnon, Surapon, Hongeng, Suradej
Format:	Artikel
Sprache:	eng
Schlagworte:	Chemotherapy Children Hematopoietic stem cells high risk Immunotherapy Medical prognosis Neuroblastoma non‐immunotherapy Oncology outcomes Patients Pediatrics Retinoic acid Solid tumors Stem cell transplantation Thailand Topotecan
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!